Background. Estimation of influenza vaccine effectiveness (VE) among older adults at high risk of serious complications of influenza infection is challenging. These challenges include identifying and adjusting for potential confounders. The rarity of documented influenza deaths, even among individuals at greatest risk, makes VE assessment for this outcome particularly difficult. Thus, population-level linkages of public health system records are helpful in estimating VE for preventing death.
Background. Pregnant women are at greater risk of complications from influenza (flu) infection than the general population. Although vaccination is an effective method to prevent influenza, the vaccine is underutilized during pregnancy. A challenge to maternal flu vaccination is the paucity of data about the effectiveness of inactivated influenza vaccines (IIV) in preventing severe outcomes in pregnant women. To inform policy and address this knowledge gap, CDC developed a multi-country collaboration to investigate the preventive value of IIV during pregnancy during multiple flu seasons. We present the progress to date of this Network.
Methods. PREVENT was established in April 2016 to: i) estimate incidence of influenza and vaccination rates; ii) describe epidemiologic characteristics associated with illness; and iii) estimate IIV effectiveness in preventing hospitalizations during pregnancy associated with RT PCR -confirmed influenza. We selected sites that could identify the population of women known to be pregnant during flu seasons and integrate their hospitalization data, clinical laboratory testing, and vaccination records. We will assess VE using the case test-negative control design and use meta-analyses to pool VE estimates across sites and account for significant differences. Primary analyses will be completed by August 2017.
Results. Seven sites in Australia, Canada, Israel, and the US were selected; a protocol and data dictionary were finalized. We identified 1,024 pregnant women hospitalized with acute respiratory illness and RT-PCR tested, during six influenza seasons (2010-11 through 2015-16) . Of the qualifying women, 550 (54%) tested positive for flu. Positivity varied by site (range 41% (US)-61.8% (Ontario, CAN)), and vaccination coverage varied across sites and seasons (range 7.3% (Ontario, CAN)-46% (US)). Analyses will examine flu season characteristics, vaccination patterns, and clinical and birth outcomes related to respiratory illness during pregnancy and flu incidence.
Conclusion. Laboratory-confirmed influenza hospitalization during pregnancy is a relatively low-frequency event. Pooling data across multiple sites offers a way to estimate VE against severe influenza outcomes in pregnant women that is informative to influenza vaccine policy. Background. Influenza continues to cause significant morbidity and mortality each year. Vaccination is the primary prevention; however, its effectiveness may be limited even among young, healthy adults. Vitamin D deficiency is highly prevalent and may be associated with poor vaccine immunogenicity and an increased risk for respiratory infections.
Methods. We conducted a retrospective cross-sectional study among young, healthy military personnel to evaluate the associations between 25(OH)D levels with post-influenza vaccination antibody titers (seroprotection defined as a titer of ≥1:40 post-vaccination) and healthcare encounters for respiratory infections during the 2009-2010 influenza season. 25(OH)D levels were analyzed as continuous and categorical [normal (>30 ng/mL), insufficient (20-30 ng/mL), and deficient (<20 ng/mL)] variables. Separate univariate and multivariable logistic regression models were utilized to determine the associations between 25(OH)D levels with antibody responses and respiratory conditions adjusting for possible confounders.
Results. A total of 437 subjects were evaluated. Most participants were young adults (91% were 18-39 years of age), 50% were male, and 56% resided in the southern U.S. Overall, 152 (35%) were vitamin D deficient, 167 (38%) insufficient, and 118 (27%) had normal 25(OH)D levels. There were no demographic differences by 25(OH)3 category. Only 224 (51%) demonstrated a seroprotective anti-influenza post-vaccination titer, which did not vary by categorical 25(OH)D levels 
